- $246.37m
- $141.34m
- 55
- 34
- 87
- 60
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.27 | ||
| Price to Tang. Book | 2.27 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -18.65% | ||
| Return on Equity | -13.01% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Eliem Therapeutics, Inc. is a biotechnology company. The Company is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. Its clinical-stage program, ETX-155, is an investigational, oral, neuroactive steroid NCE that is designed to act as a positive allosteric modulator (PAM) of the GABAA receptor (GABAAR). The GABAA PAM neuroactive steroid class has been clinically validated in depression and epilepsy, with Sage Therapeutics receiving approval from the United States. ETX-155 for use in multiple disorders of high unmet need, including major depressive disorder (MDD) and focal onset seizures (FOS). It has designed several lead series based on novel chemistry and selected a lead clinical candidate, ETX-123. The ETX-123 molecule displays potent activation of Kv7.2/3 in vitro with an approximately 0.7 nM EC50.
Directors
- Andrew Levin NEC (44)
- Robert Azelby CEO (53)
- Erin Lavelle CFO (43)
- Valerie Morisset EVP (51)
- James Bucher EVP (54)
- Amy Chappell EXO
- Judith Dunn IND (59)
- Leone Patterson IND (58)
- Liam Ratcliffe IND (58)
- Adam Rosenberg IND (51)
- Simon Tate IND (55)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- October 18th, 2018
- Public Since
- August 10th, 2021
- No. of Shareholders
- 15
- No. of Employees
- 9
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 29,091,166
- Address
- 2801 CENTERVILLE ROAD 1ST FLOOR, WILMINGTON, 19808
- Web
- https://eliemtx.com/
- Phone
- +1 4252762300
- Contact
- Christopher Brinzey
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for ELYM
Similar to ELYM
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
As of Today at 20:28 UTC, shares in Eliem Therapeutics are trading at $8.29. This share price information is delayed by 15 minutes.
Shares in Eliem Therapeutics last closed at $8.29 and the price had moved by +177.26% over the past 365 days. In terms of relative price strength the Eliem Therapeutics share price has outperformed the S&P500 Index by +120.62% over the past year.
The overall consensus recommendation for Eliem Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Eliem Therapeutics does not currently pay a dividend.
Eliem Therapeutics does not currently pay a dividend.
Eliem Therapeutics does not currently pay a dividend.
To buy shares in Eliem Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $8.29, shares in Eliem Therapeutics had a market capitalisation of $241.17m.
Here are the trading details for Eliem Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: ELYM
Based on an overall assessment of its quality, value and momentum Eliem Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Eliem Therapeutics is $4.00. That is 51.75% below the last closing price of $8.29.
Analysts covering Eliem Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.52 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Eliem Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +176.47%.
As of the last closing price of $8.29, shares in Eliem Therapeutics were trading +117.75% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Eliem Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $8.29.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Eliem Therapeutics' management team is headed by:
- Andrew Levin - NEC
- Robert Azelby - CEO
- Erin Lavelle - CFO
- Valerie Morisset - EVP
- James Bucher - EVP
- Amy Chappell - EXO
- Judith Dunn - IND
- Leone Patterson - IND
- Liam Ratcliffe - IND
- Adam Rosenberg - IND
- Simon Tate - IND